CRYSTAL DEPOSITION DISEASES: Edited by Hyon ChoiUricosuric drugs the once and future therapy for hyperuricemia?Bach, Mary H.; Simkin, Peter A. Author Information Department of Medicine, Division of Rheumatology, University of Washington, Seattle, Washington, USA Correspondence to Mary H. Bach, MD, PharmD, Department of Medicine, University of Washington, Box 358280, Seattle, WA 98195, USA. Tel: +1 206 314 3850; e-mail: [email protected] Current Opinion in Rheumatology: March 2014 - Volume 26 - Issue 2 - p 169-175 doi: 10.1097/BOR.0000000000000035 Buy Metrics Abstract Purpose of review Although uricosuric agents provide the most time-honoured approach to the control of hyperuricemia, their place in the armamentarium has been eclipsed by that of xanthine oxidase inhibitors. This review considers the potential for uricosuric agents from the perspective of recent progress in the understanding of urate transport systems. Recent findings No new agents have yet become available, but promising new drugs are under development. Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia. Summary Conceptually, modest inhibition of renal tubular reabsorption should provide effective relief for the millions of individuals who are now hyperuricemic and who suffer from its principal consequence, gout. © 2014 Lippincott Williams & Wilkins, Inc.